Ricardo Grieshaber-Bouyer
Company: Friedrich-Alexander-Universität Erlangen-Nürnberg
Job title: Professor
Seminars:
Panel Discussion: Investigating Preclinical Platforms for Autoimmune T-Cell Engagers From Human Relevant Assays to Regulatory Confidence 2:40 pm
For TCEs in autoimmunity, conventional preclinical tools, often adapted from oncology, fall short in capturing the inflammatory, chronic, and tissue-specific nature of disease. This panel will explore how to build assays that reflect real autoimmune biology, capture safety-relevant signals, and avoid reliance on transgenic animals. With human target expression and immune context being essential, developers…Read more
day: Day Two
Chair’s Opening Remarks 8:55 am
day: Day Two
Overviewing T-Cell Engager Success in Autoimmunity & Taking Learnings From Oncology For Efficacy, Safety & Smarter Design 9:00 am
Gaining a high-level overview of the current TCE pipeline in autoimmunity, including lessons learned from oncology programs and key distinctions in target biology and patient needs Exploring how biotech and pharmaceutical companies are repurposing or adapting B-cell and plasma-cell depleting assets originally built for oncology for use in RA, lupus, and other autoimmune diseases Investigating…Read more
day: Day One
Panel Discussion: TCEs vs Cell Therapy: Comparing the Pros & Cons to Build Smarter Pipelines with the Right Modality for the Right Target 11:00 am
As T-cell engagers (TCEs) rapidly emerge from oncology into the autoimmune space, the field is facing a crucial inflection point: how do TCEs stack up against T-cell therapies in terms of specificity, efficacy, and durability? This panel brings together leading voices spanning TCE and cell therapy modalities to debate how these technologies co-exist, compete, or…Read more
day: Day One
Chair’s Opening Remarks 8:55 am
day: Day One